An imbalance between proinflammatory and regulatory processes underlies autoimmune disease pathogenesis. We have shown that acute relapses of multiple sclerosis are characterized by a deficit in the immune suppressive ability of CD8+ T cells. These cells play an important immune regulatory role, mediated in part through cytotoxicity (perforin [PRF]/granzyme [GZM]) and IFNγ secretion. In this study, we further investigated the importance of IFNγ–, GZMB-, PRF1-, and LYST-associated pathways in CD8+ T cell–mediated suppression. Using the CRISPR-Cas9 ribonucleoprotein transfection system, we first optimized efficient gene knockout while maintaining high viability in primary bulk human CD8+ T cells. Knockout was confirmed through quantitative real-time PCR assays in all cases, combined with flow cytometry where appropriate, as well as confirmation of insertions and/or deletions at genomic target sites. We observed that the knockout of IFNγ, GZMB, PRF1, or LYST, but not the knockout of IL4 or IL5, resulted in significantly diminished in vitro suppressive ability in these cells. Collectively, these results reveal a pivotal role for these pathways in CD8+ T cell–mediated immune suppression and provide important insights into the biology of human CD8+ T cell–mediated suppression that could be targeted for immunotherapeutic intervention.
T helper 17 (Th17) CD4+ T cells are key mediators of autoimmune pathology. Interleukin (IL)-1β is a potent proinflammatory cytokine known to promote Th17 differentiation and pathogenicity, in combination with other cytokines. Whereas recent studies have shown that T cells are capable of expressing IL-1β themselves, the role of this T cell–endogenous IL-1β is poorly understood. Using CRISPR/Cas9-mediated deletion of IL1B in naïve human CD4+ T cells along with cytokine neutralization and IL-1 receptor blockade, we found that T cell–intrinsic IL-1β is not essential for Th17 differentiation or effector resistance. Remarkably, single-cell RNA sequencing revealed that IL1B deletion profoundly rewires the transcriptional and metabolic landscape within the T cells, suppressing glycolytic and hypoxia-responsive pathways. These findings uncouple T cell–intrinsic IL-1β from Th17 effector resistance while uncovering an important contribution toward sustaining metabolic roles. This refines our understanding of IL-1β biology and informs therapeutic strategies in immune-mediated disease settings.